Stockscreener 앱 받기
0.8314
1.13%
0.0093
시간 외 거래:
.83
-0.0014
-0.17%
Briacell Therapeutics Corp 주식(BCTX)의 최신 뉴스
BriaCell Therapeutics Announces Closing of $15 million Public Offering - GlobeNewswire
BriaCell Therapeutics Secures $15 Million in Public Offering - TipRanks
BriaCell Secures $15M Funding Boost for Cancer Immunotherapy Development at $1.25 Per Unit - Stock Titan
BCTX files $15M unit offering; share count could triple post-deal | CMCL SEC FilingForm 6-K - Stock Titan
BriaCell Prices $15 Mln Public Offering To Fund Operations And Growth Initiatives - Nasdaq
BriaCell Therapeutics (BCTX) Plunges 61.78% After $15M Public Offering - AInvest
BriaCell (BCTX) Announces $15M Public Offering of Common Shares and Warrants | BCTX Stock News - GuruFocus
BriaCell Therapeutics Announces Pricing of $15 million Public Offering | BCTX Stock News - GuruFocus
BriaCell says $15M unit offering prices at $1.25 per unit - TipRanks
Briacell Therapeutics announces pricing of $15 million public offering - MarketScreener
BriaCell Therapeutics Announces Pricing of $15 million Public Offering - GlobeNewswire
Cancer Immunotherapy Developer BriaCell Secures $15M Funding: What the Deal Means for Investors - Stock Titan
BCTX Stock Surges Amid Positive Developments and Strategic Moves - StocksToTrade
(BCT) Proactive Strategies (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Adds Mayo Clinic to Late-Stage Study in Metastatic Breast Cancer - MarketScreener
BriaCell adds Mayo Clinic to Phase 3 study in metastatic breast cancer - TipRanks
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer - GlobeNewswire
Mayo Clinic Partners with BriaCell for Groundbreaking Phase 3 Breast Cancer Immunotherapy Study - Stock Titan
When the Price of (BCT) Talks, People Listen (BCT:CA) - news.stocktradersdaily.com
BriaCell Shares Slide 22% After Announcing Dilutive Public Offering - MSN
Briacell stock maintains Buy rating at H.C. Wainwright on strong survival data - Investing.com Australia
BriaCell Therapeutics Corp. - Baystreet.ca
BriaCell announces updated Phase 2 survival data fro Bria-IMT - TipRanks
BriaCell’s Bria-IMT Shows Promising Survival Advantage in Metastatic Breast Cancer - TipRanks
BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer - GlobeNewswire
Clinical Trial: New Breast Cancer Drug Shows 17.3-Month Survival Rate, Beating Current Standard of Care - Stock Titan
BriaCell Achieves Milestone in Metastatic Breast Cancer Study with Bria-OTS - TipRanks
Promising Clinical Developments and Positive Outlook Justify Buy Rating for BriaCell Therapeutics - TipRanks
BriaCell’s Bria-IMT Shows Promising Results in Advanced Breast Cancer Treatment - TipRanks
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient - Santé log
BriaCell Reports Complete and Sustained Resolution of Brain - GlobeNewswire
Breakthrough: Complete Brain Tumor Resolution in Patient Who Failed 8 Prior Cancer Treatments - Stock Titan
BriaCell Therapeutics Corp (BCTX) Plunges 29.55% Amid Public Offering Concerns - AInvest
BriaCell Therapeutics stock tumbles after announcing public offering By Investing.com - Investing.com South Africa
BriaCell Therapeutics stock tumbles after announcing public offering - Investing.com
BriaCell Plunges 23.33% Amid IPO Registration Amendments - AInvest
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study - Santé log
BriaCell Patient Achieves Sustained Complete Resolution of - GlobeNewswire
Breakthrough: BriaCell's Cancer Therapy Eliminates Lung Metastasis in Advanced Breast Cancer Patient - Stock Titan
BriaCell reports 52% one-year survival rate in metastatic breast cancer trial By Investing.com - Investing.com South Africa
Form FWP BriaCell Therapeutics Filed by: BriaCell Therapeutics Corp. - StreetInsider
BriaCell’s Phase 2 Study Shows Promising Survival Rates in Metastatic Breast Cancer - TipRanks
BriaCell reports 52% one-year survival rate in metastatic breast cancer trial - Investing.com
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer - GlobeNewswire
Breakthrough: New Cancer Drug Shows 52% Survival Rate Where Standard Treatments Failed - Stock Titan
BriaCell Expands Phase 3 Cancer Study with New Clinical Sites - TipRanks
BriaCell Highlights Additional Phase 3 Clinical Sites - GlobeNewswire
BriaCell adds two major cancer centers to Phase 3 breast cancer study - Investing.com
BriaCell’s Phase 3 Study in Metastatic Breast Cancer Receives Positive DSMB Recommendation - TipRanks
BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT) - The Globe and Mail
BriaCell Reports Increased Losses in Latest Financials - TipRanks
(BCT) Advanced Trading Insights (BCT:CA) - news.stocktradersdaily.com
Briacell Therapeutics Corp expected to post a loss of $1.76 a shareEarnings Preview - TradingView
Learn to Evaluate (BCT) using the Charts (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Schedules Virtual Investor Presentations for June 2025 - TipRanks
BriaCell WRT BCTXZ 2025Q3 Earnings Preview Upside Ahead on Projected Revenue Growth - AInvest
(BCT) Strategic Equity Report (BCT:CA) - news.stocktradersdaily.com
(BCT) Investment Analysis and Advice (BCT:CA) - news.stocktradersdaily.com
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26 - GlobeNewswire
(BCT) Pivots Trading Plans and Risk Controls (BCT:CA) - news.stocktradersdaily.com
Stocks In Play - Baystreet.ca
Stocks in play: BriaCell Therapeutics Corp. - The Globe and Mail
0.64%
0.37%
자본화:
|
볼륨(24시간):